Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ImmunoGen, Inc.    IMGN   US45253H1014

IMMUNOGEN, INC. (IMGN)

28
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Sales16,435,559,989,383,379,4
Operating income (EBITDA)--68,4-66,9-54,9-85,9-78,1
Operating profit (EBIT)-73,3-73,0-71,5-58,9-109-106
Pre-Tax Profit (EBT)-73,3-72,8----
Net income-73,3-72,8-71,4-60,9-117-113
EPS ( $)-0,95-0,87-0,83-0,70-1,36-1,30
Dividend per Share ( $)------
Yield------
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Debt------
Finance-19514218212368,4
Operating income (EBITDA)--68,4-66,9-54,9-85,9-78,1
Leverage
(Debt/EBITDA)
------
Capital Expenditure2,903,778,187,917,827,83
Book Value Per Share (BVPS)-1,44 $0,88 $0,48 $-0,57 $0,23 $
Cash Flow per Share--0,72 $-0,63 $0,50 $-0,87 $-1,16 $
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Balance Sheet Analysis
Assessed data source :
© 2015 Thomson Reuters
Advertisement
Financial Ratios

Size 2015e 2016e
Capitalization 766 M$ -
Entreprise Value (EV) 584 M$ 643 M$
Valuation 2015e 2016e
PER (Price / EPS)
Capitalization / Revenue 8,58x 9,20x
EV / Revenue 6,54x 7,72x
EV / EBITDA -10,6x -7,49x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 18,6x -15,7x
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) -66,0% -131%
operating Leverage (Delta EBIT / Delta Sales) 0,36x -12,8x
Net Margin (Net Profit / Revenue) -68,2% -141%
ROA (Net Profit / Asset) -27,5% -39,2%
ROE (Net Profit / Equities) -78,5% -149%
Rate of Dividend - -
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   8,86% 9,38%
Cash Flow / Sales (Taux d'autofinancement) 48,0% -89,7%
Capital Intensity (Assets / Sales) 2,48x 3,60x
Financial Leverage (Net Debt / EBITDA) 3,32x 1,43x
EPS & Dividend